Cancer that has spread to areas like the lungs can apply the brakes to a natural pathway that should recruit killer T cells directly to where it has metastasized, scientists report.
Mar 28, 2023
0
48
Researchers at The University of Texas MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer (NSCLC), highlighting a novel therapeutic ...
Feb 13, 2023
0
38
A new study that analyzed the tumor microenvironment of pancreatic cancer revealed the cause of tumor cell resistance to immunotherapy and resulted in new treatment strategies.
Jan 26, 2023
0
61
A new library documenting hundreds of mutations can help to explain why some cancers don't respond to immunotherapies, and highlights potential pathways that could be drug targets in the future.
Jan 20, 2023
0
6
Researchers from the University of Michigan Rogel Cancer Center have found a mechanism for why a subset of patients' tumors grow, rather than shrink, when faced with immunotherapy.
Jan 18, 2023
0
40
A team led by researchers at NYU Langone Health's Perlmutter Cancer Center has identified a gene that drives development of the second most common type of lung carcinoma, offering greater insight into how the disease might ...
Jan 9, 2023
0
58
At any time, most cancer patients are receiving a treatment that does not significantly benefit them while they endure bodily and financial toxicity. Aiming to guide each patient to the most optimal treatment, precision medicine ...
Dec 20, 2022
0
63
An experimental therapy has shown promise in preclinical models as treatment for an aggressively spreading type of colorectal cancer, according to a new study by Weill Cornell Medicine investigators.
Dec 15, 2022
0
51
The most comprehensive study of kidney cancer at single-cell level has discovered a potential drug target to treat renal cell carcinoma, a cancer with a high mortality rate that is hard to detect. Researchers from the Wellcome ...
Nov 25, 2022
0
853
A team of researchers mapping a molecular atlas for ductal carcinoma in situ (DCIS) has made a major advance toward distinguishing whether the early pre-cancers in the breast will develop into invasive cancers or remain stable.
Nov 18, 2022
0
60
